Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Achieve Life Sciences (ACHV) Non-Current Assets (2016 - 2026)

Achieve Life Sciences (ACHV) has disclosed Non-Current Assets for 17 consecutive years, with $2.0 million as the latest value for Q1 2026.

  • Quarterly Non-Current Assets fell 13.32% to $2.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Mar 2026, down 13.31% year-over-year, with the annual reading at $1.9 million for FY2025, 12.23% down from the prior year.
  • Non-Current Assets for Q1 2026 was $2.0 million at Achieve Life Sciences, up from $1.9 million in the prior quarter.
  • The five-year high for Non-Current Assets was $2.9 million in Q1 2022, with the low at $1.9 million in Q4 2025.
  • Average Non-Current Assets over 5 years is $2.4 million, with a median of $2.4 million recorded in 2024.
  • The widest YoY moves for Non-Current Assets: up 1.64% in 2025, down 16.88% in 2025.
  • Achieve Life Sciences' Non-Current Assets stood at $2.6 million in 2022, then dropped by 9.54% to $2.4 million in 2023, then decreased by 9.33% to $2.2 million in 2024, then dropped by 12.23% to $1.9 million in 2025, then grew by 7.52% to $2.0 million in 2026.
  • Per Business Quant, the three most recent readings for ACHV's Non-Current Assets are $2.0 million (Q1 2026), $1.9 million (Q4 2025), and $2.0 million (Q3 2025).